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INTRODUCTION
Recent clinical studies have demonstrated an emerging subgroup of head and neck cancers that are virally mediated. This disease appears to be 
a distinct clinical entity with patients presenting with highly radiosensitive tumours (Figure 1).  Patients with oropharyngeal tumours positive for 
human papillomavirus also present younger, with more advanced nodal disease and with a lower exposure to tobacco and alcohol.  Consequently 
they are living longer, often with the debilitating functional side effects of treatment.  This study forms Phase 1 of a wider project whose primary 
objective is to determine the response of virally mediated nasopharyngeal and oropharyngeal cancers to radiation therapy treatment.  It will include 
the determination of risk categories and corresponding adaptive treatment management strategies to pre-emptively manage these patients.  The 
aim of Phase 1 of the project was to retrospectively evaluate patients with virally mediated tumours in order to generate preliminary risk profiles 
and treatment management strategies to test in a prospective setting.
METHODS
Phase 1 of the investigation involved a retrospective cohort study.  Criteria for inclusion in the study were as follows:
 • Treatment at Princess Alexandra Hospital Radiation Oncology Department between 2005-2010
 • Histologically confirmed nasopharyngeal or oropharyngeal carcinoma
 • Known positive viral status (Human Papillomavirus or Epstein Barr Virus)
 • Any stage disease
 • Node positive 
 • Curative radiotherapy treatment intent with or without chemotherapy
 
Patient demographics and tumour characteristics including age, gender, diagnosis, TNM stage, pre-treatment nodal size and treatment delivered 
were recorded.  Each patient’s treatment plan was reviewed to determine if another computed tomography (re-CT) scan was performed and at what 
time point (dose/fraction) this occurred.  The justification for this re-CT was determined using four categories: primary tumour volume regression, 
nodal volume regression, weight loss or a combination of these factors 
Patients who underwent a re-CT were further investigated to determine numerous other factors including magnitude of weight loss, primary 
tumour volume regression, nodal tumour volume regression and whether a new radiotherapy plan was generated.  If a re-plan was performed, the 
dosimetric effect was quantified by comparing dose volume histograms of gross target volumes (primary and nodal tumour volumes) and critical 
structures from the actual treatment delivered and the original treatment plan.  The purpose of this comparison was to evaluate the effect of re-
planning or adaptive treatment management in these cases. 
The data collected from this assessment was analysed using the Stata program to identify the major determining factors involved in the requirement 
of this group of patients to undergo a re-CT and/or replan.  Preliminary statistical analysis included basic descriptive statistics and linear regression 
models.  Specific factors focused on included nodal size and timing of required interventions.  Future statistical analysis will include the use of 
Bayesian networks and classification and regression trees.
STATISTICAL CONSIDERATIONS
121 patients were eligible for inclusion in the study.  The demographics of this cohort are described in Table 1.
 • 25/121 (20.7%) patients required a re-CT and these re-CTs were performed between fractions 20 to 25 of treatment
 • Justification for re-CTs appeared to consist of a combination of primary tumour volume and/or nodal tumour volume regression and    
  weight loss  
 • 16/25 (13.2%) patients had a replan generated 
 • 7 of these replans were implemented clinically due to the significance of the resultant dosimetric effect  
A comparison of variables for patients who underwent a re-CT during their course of treatment and those that did not can be seen in Table 2 and 
Figure 2.  2 patients (one re-CT patient and one non re-CT patient) were excluded in the generation of the plot in Figure 2 due to their extreme nodal 
sizes.  Specific information relating to those patients who underwent a re-CT during their treatment course is described in Table 3.
Although primary tumour volume regression was seen in the patients studied, nodal size and subsequent regression was found to be a primary 
contributing factor to the requirement of these patients to undergo some type of adaptive treatment management during their radiotherapy.  Most 
other variables, including TNM staging, tumour differentiation and smoking history, were similar amongst the cohort and have not yet shown to 
have a significant effect with linear regression models. 
 
Weight loss throughout treatment was found to be a contributing factor to the need for a re-CT to be performed.  However, preliminary analysis of 
this data has not yet demonstrated any clearly defined threshold levels that could be applied to specific risk profile generation. 
RESULTS
DISCUSSION
The following preliminary risk profiles have been hypothesised:
 • Low risk category (minimal need for adaptive treatment management)
   • Viral negative disease
   • Viral positive disease with nodal size ≤ 35mm
 • Intermediate risk category (possible need for adaptive treatment management)
   • Viral positive disease with dominant nodal size 36mm – 45mm
 • High risk category (highly likely to need adaptive treatment management)
   • Viral positive disease with dominant nodal size ≥ 46mm
 
The timing of this adaptive treatment intervention is still being investigated but preliminary results suggest that a re-CT should be performed at 20 
fractions (or approximately 4 weeks into the patient’s treatment) for those in the intermediate and high risk categories.
 
The results of this study indicate that a subset of virally mediated head and neck cancers respond significantly during radiation treatment.  Implications 
of this response are the potential underdosing or overdosing of tumour and/or surrounding critical structures.  Consequently, the development of 
adaptive treatment strategies that improve organ sparing for this patient group is important to ensure delivery of the prescribed dose to the tumour 
volume whilst minimizing the dose received to surrounding critical structures.  This could reduce side effects and improve overall patient quality 
of life.
CONCLUSION
The generation of risk profiles and associated treatment management strategies is particularly important to determine the optimal process for 
implementation of adaptive treatment planning that provides maximum benefit, in terms of efficacy and efficiency, for both patients and busy 
radiotherapy departments.  
 
Due to the dynamic nature of this group of patients, further statistical analysis is required to more accurately define appropriate risk profiles that 
can be utilised in their treatment management.  The resultant risk profiles and associated adaptive treatment approaches developed in this study 
will be tested prospectively in the clinical setting in Phase 2 of this investigation.
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Table 1  Selected patient characteristics
Characteristics Number
Sex
      Male 106
     Female 15
Age mean (range) 54 (22-81)
Primary tumour site
     Tonsil 65
     Base of tongue 34
     Other 6
Nasopharynx 16
T classification
     0 2
     1 26
     2 38
     3 34
     4 21
N classification
     1 12
     2 93
     3 16
Smoking history
     Never 39
     Former 49
     Active 33
Nodal size mean (range) 37.1mm (13mm-150mm)
Re-CT performed 25
Replan generated 16
Table 2  Re-CT vs No Re-CT patient characteristics
Characteristic Re-CT SD No Re-CT SD
Mean T classification 2 1 2 1
Mean N classification 2 0.6 2 0.4
Mean tumour differentiation Poorly or 
undifferentiated
- Poorly or 
undifferentiated
-
Mean smoking history Former smoker - Former smoker -
Mean nodal size (mm) 44.2* 21.3* 32.7* 11.9*
Mean nodal size for patients 
with replan generated (mm)
44.8* 21.25* 33.2* 12.8*
SD - Standard deviation
* Removal of outlying measurements
Table 3  Specific Re-CT patient characteristics
Characteristic Re-CT
Mean initial weight (kg) 82.8
Mean weight at re-CT (kg) 76.9
Mean weight loss (%) 7.1
Mean initial primary GTV (cc) 30.9
Mean primary GTV at re-CT (cc) 19.9
Mean primary GTV reduction (%) 35.6
Mean initial nodal GTV at re-CT (cc) 59.8*
Mean nodal GTV at re-CT (cc) 36.8*
Mean nodal GTV reduction (%) 38.5
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